Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects

NCT ID: NCT00621699

Last Updated: 2008-02-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2007-11-30

Brief Summary

The purpose of this study is to confirm a significant influence of ezetimibe and tacrolimus on each others pharmacokinetics

Detailed Description

Hypercholesterolemia is a frequent finding in organ transplant recipients receiving immunosuppressive drugs such as tacrolimus. To prevent increased cardiovascular morbidity and mortality in these patients, co-medication with lipid-lowering statins is recommended. However, treatment with statins is limited in many patients by insufficient cholesterol-lowering efficacy, drug interactions and serious adverse drug reactions (e.g. rhabdomyolysis). These patients may benefit from comedication with the cholesterol absorption inhibitor ezetimibe. Since tacrolimus and ezetimibe were shown to be substrates of the efflux transporter ABCB1 (P-glycoprotein), drug interactions between both compounds may occur. Therefore, this clinical study in healthy subjects was initiated to evaluate the clinical relevance of drug/drug interactions between tacrolimus and ezetimibe according to the accepted bioequivalence approach.

Conditions

Pharmacokinetics; Drug Interactions; Hypercholesterolemia; Immunosuppression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

C

administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)

Group Type: EXPERIMENTAL

1 tablet Ezetrol(R) + 1 capsules Prograf(R)

Intervention Type: DRUG

administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling

A

administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)

Group Type: ACTIVE_COMPARATOR

1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany

Intervention Type: DRUG

administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling

B

administration of 1 capsule Prograf(R) (5 mg tacrolimus)

Group Type: ACTIVE_COMPARATOR

1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany

Intervention Type: DRUG

administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling

Interventions

1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany

administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling

Intervention Type: DRUG

1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany

administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling

Intervention Type: DRUG

1 tablet Ezetrol(R) + 1 capsules Prograf(R)

administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling

Intervention Type: DRUG

Other Intervention Names

Ezetrol; Prograf; Ezetrol+Prograf

Eligibility Criteria

Inclusion Criteria

• age: 18 - 45 years
• sex: male and female
• ethnic origin: Caucasian
• body weight: 19 kg/m² to 27 kg/m²
• good health as evidenced by the results of the clinical examination, ECG, and the laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state
• written informed consent

Exclusion Criteria

• known allergy to macrolide antibiotics
• existing cardiac or hematological diseases and/or pathological findings which might interfere with safety, pharmacodynamic effect and/or pharmacokinetics of ezetimibe and sirolimus
• existing hepatic and renal diseases and/or pathological findings which might interfere with safety, pharmacodynamic effect and/or pharmacokinetics of ezetimibe and sirolimus
• existing gastrointestinal diseases and/or pathological findings which might interfere with safety, pharmacodynamic effect and/or pharmacokinetics of ezetimibe and sirolimus
• acute or chronic diseases which could affect drug absorption or metabolism
• history of any serious psychological disorder
• drug or alcohol dependence
• positive drug or alcohol screening
• smokers of 10 or more cigarettes per day
• positive screening results for HIV, HBV and HCV
• volunteers who are on a diet which could affect the pharmacokinetics of the drug
• heavy tea or coffee drinkers (more than 1L per day)
• lactation and pregnancy test positive or not performed
• volunteers suspected or known not to follow instructions
• volunteers who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
• volunteers liable to orthostatic dysregulation, fainting, or blackouts
• blood donation or other blood loss of more than 400 ml within the last 12 weeks prior to the start of the study
• participation in a clinical trial during the last 3 months prior to the start of the study
• less than 14 days after last acute disease
• any systemically available medication within 4 weeks prior to the intended first administration unless, because of the terminal elimination half-life, complete elimination from the body can be assumed for the drug and/or its primary metabolites (except oral contraceptives)
• repeated use of drugs during the last 4 weeks prior to the intended first administration, which can influence hepatic biotransformation (e.g. barbiturates, cimetidine, phenytoin, rifampicin)
• repeated use of drugs during the last 2 weeks prior to the intended first administration which affect absorption (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists)
• intake of grapefruit containing food or beverages within 7 days prior to administration
• known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparation
• subjects with severe allergies or multiple drug allergies

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Medicine Greifswald

OTHER

Sponsor Role: lead

Responsible Party

Department of Clinical Pharmacology

Principal Investigators

Werner Siegmund, Prof

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Pharmacology

Locations

Department of Clinical Pharmacology

Greifswald, , Germany

Countries

Germany

Other Identifiers

2006-006549-14

Identifier Type: -

Identifier Source: secondary_id

Eze-Tacro

Identifier Type: -

Identifier Source: org_study_id